# US 2026/0092048 A1 · Solid forms and salts of a quinoline cgas antagonist compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092048 A1
- Document ID: US20260092048A1
- Status: Published application
- Kind: A1
- Application number: 19/316,546
- Filed: 2025-09-02
- Published: 2026-04-02
- Earliest claimed: 2024-08-30
- Assignees: ImmuneSensor Therapeutics, Inc.; Board of Regents, The University of Texas System
- Applicants: ImmuneSensor Therapeutics, Inc.; The Board of Regents of the University of Texas System
- Inventors: Jian Qiu; Qi Wei; Heping Shi; Lijun Sun; Zhijian Chen
- Web page: https://patentgrep.com/patent/US20260092048A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides compounds that are cGAS antagonists, solid forms of the compounds, methods of preparation of the compounds and their solid forms, pharmaceutical compositions comprising the compounds and their solid forms, and their use in medical therapy.

## Claims

### Claim 1

A compound, wherein the compound is a solid form of Compound A:

### Claim at position 2

2-8. (canceled)

### Claim 9

A compound, wherein the compound is a pharmaceutically acceptable salt of Compound A:
wherein the pharmaceutically acceptable salt is selected from a hydrochloride, sulfate, napadisylate, esylate, mesylate, napsylate, besylate, sodium, potassium, L-arginine, choline, L-lysine, t-butylamine, meglumine, and tris(hydroxymethyl)aminomethane salt.

### Claim at position 4

10-14. (canceled)

### Claim 15 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is an esylate salt.

### Claim at position 6

16-17. (canceled)

### Claim 18 (depends on 15)

The compound of claim 15, wherein Compound A esylate is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 6.0±0.2, 11.5±0.2, 13.3±0.2, 18.6±0.2, 19.5±0.2, 20.9±0.2, 22.1±0.2, 22.8±0.2, 23.9±0.2, 24.6±0.2, 25.4±0.2, and 29.1±0.2.

### Claim at position 8

19-21. (canceled)

### Claim 22 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is a t-butylamine salt.

### Claim at position 10

23-24. (canceled)

### Claim 25 (depends on 22)

The compound of claim 22, wherein Compound A t-butylamine salt is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 6.4±0.2, 6.6±0.2, 11.4±0.2, 13.4±0.2, 15.0±0.2, 17.7±0.2, 17.9±0.2, 21.0±0.2, 21.4±0.2, 22.1±0.2, and 26.1±0.2.

### Claim at position 12

26-28. (canceled)

### Claim 29 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is tris(hydroxymethyl)aminomethane salt.

### Claim at position 14

30-31. (canceled)

### Claim 32 (depends on 29)

The compound of claim 29, wherein Compound A tris(hydroxymethyl)aminomethane salt is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 3.7±0.2, 7.5±0.2, 11.2±0.2, 15.0±0.2, 17.8±0.2, 18.4±0.2, 18.8±0.2, 19.0±0.2, 19.7±0.2, 20.6±0.2, 21.5±0.2, 22.4±0.2, 22.6±0.2, 25.0±0.2, 25.7±0.2, 26.4±0.2, 27.8±0.2, 28.7±0.2, 29.2±0.2, and 29.3±0.2.

### Claim at position 16

33-35. (canceled)

### Claim 36 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is hydrochloride salt.

### Claim 37 (depends on 36)

The compound of claim 36, wherein Compound A hydrochloride salt is a solid form and is Compound A hydrochloride salt Type A and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 7.1±0.2; 7.9±0.2, 10.0±0.2, 12.9±0.2, 17.9±0.2, 19.3±0.2, 20.9±0.2, 21.5±0.2, 22.7±0.2, 25.1±0.2, 26.0±0.2, 27.0±0.2, and 30.7±0.2.

### Claim 38 (depends on 36)

The compound of claim 36, wherein Compound A hydrochloride salt is a solid form and is Compound A hydrochloride salt Type B and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 6.9±0.2, 8.2±0.2, 15.0±0.2, 19.8±0.2, 23.8±0.2, and 24.7±0.2.

### Claim 39 (depends on 36)

The compound of claim 36, wherein Compound A hydrochloride salt is a solid form and is Compound A hydrochloride salt Type C and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 6.1±0.2, 9.2±0.2, 18.4±0.2, 19.5±0.2, 21.8±0.2, 22.5±0.2, 23.8±0.2, and 25.0±0.2, 28.4±0.2.

### Claim 40 (depends on 36)

The compound of claim 36, wherein Compound A hydrochloride salt is a solid form and is Compound A hydrochloride salt Type D and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 4.9±0.2, 6.9±0.2, 9.5±0.2, 19.8±0.2, 22.0±0.2, 25.1±0.2, and 25.9±0.2.

### Claim 41

(canceled)

### Claim 42 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is sulfate.

### Claim 43 (depends on 42)

The compound of claim 42, wherein Compound A sulfate is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 3.4±0.2, 5.7±0.2, 6.9±0.2, 9.0±0.2, 16.8±0.2, 18.2±0.2, 20.1±0.2, 21.0±0.2, and 24.6±0.2.

### Claim 44 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is napadisylate.

### Claim 45 (depends on 44)

The compound of claim 44, wherein Compound A napadisylate is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 6.7±0.2, 8.0±0.2, 11.6±0.2, 14.7±0.2, 15.3±0.2, 15.5±0.2, 17.5±0.2, 18.6±0.2, 20.4±0.2, 20.8±0.2, 23.0±0.2, 23.4±0.2, 23.8±0.2, 24.3±0.2, 24.8±0.2, 26.7±0.2, 28.6±0.2, and 29.9±0.2.

### Claim 46 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is mesylate.

### Claim 47 (depends on 46)

The compound of claim 46, wherein Compound A mesylate is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 5.8±0.2, 11.3±0.2, 16.4±0.2, 19.8±0.2, 20.4±0.2, 21.8±0.2, 22.8±0.2, 23.3±0.2, 25.1±0.2, 25.9±0.2, and 29.7±0.2.

### Claim 48 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is napsylate.

### Claim 49 (depends on 48)

The compound of claim 48, wherein Compound A napsylate is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 9.0±0.2, 12.0±0.2, 13.0±0.2, 13.3±0.2, 15.2±0.2, 16.3±0.2, 16.8±0.2, 19.1±0.2, 19.8±0.2, 21.1±0.2, 22.0±0.2, 22.8±0.2, 23.7±0.2, 24.0±0.2, 24.2±0.2, 24.9±0.2, 25.7±0.2, 26.9±0.2, 27.4±0.2, 29.4±0.2, and 30.4±0.2.

### Claim 50 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is besylate.

### Claim 51 (depends on 50)

The compound of claim 50, wherein Compound A besylate is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 3.9±0.2, 13.3±0.2, 13.9±0.2, 14.8±0.2, 15.5±0.2, 16.3±0.2, 19.1±0.2, 19.7±0.2, 21.9±0.2, 24.9±0.2, 26.0±0.2, 26.9±0.2, and 27.6±0.2.

### Claim 52 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is sodium salt.

### Claim 53 (depends on 52)

The compound of claim 52, wherein Compound A sodium salt is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 3.2±0.2, 9.7±0.2, 13.2±0.2, 14.6±0.2, 16.2±0.2, 18.1±0.2, and 23.6±0.2.

### Claim 54 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is potassium salt, form.

### Claim 55 (depends on 54)

The compound of claim 54, wherein Compound A potassium salt is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 6.2±0.2, 9.4±0.2, 12.6±0.2, 15.9±0.2, 19.0±0.2, 24.0±0.2, and 37.7±0.2.

### Claim 56 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is L-arginine salt.

### Claim 57 (depends on 56)

The compound of claim 56, wherein Compound A L-arginine salt is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 6.3±0.2, 9.3±0.2, 12.7±0.2, 18.6±0.2, 19.1±0.2, 19.6±0.2, 21.0±0.2, 21.5±0.2, 22.0±0.2, 22.8±0.2, 23.9±0.2, 24.1±0.2, 24.9±0.2, 25.7±0.2, 27.3±0.2, 27.6±0.2, 28.1±0.2, 29.8±0.2, and 30.3±0.2.

### Claim 58 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is choline salt.

### Claim 59 (depends on 58)

The compound of claim 58, wherein Compound A choline salt is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 5.6±0.2, 8.4±0.2, 11.4±0.2, 14.4±0.2, 15.3±0.2, 17.1±0.2, 20.3±0.2, 24.0±0.2, 25.9±0.2, and 28.8±0.2.

### Claim 60 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is L-lysine salt.

### Claim 61 (depends on 60)

The compound of claim 60, wherein Compound A L-lysine salt is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 5.2±0.2, 7.9±0.2, 8.7±0.2, 12.2±0.2, 13.6±0.2, 15.4±0.2, 17.3±0.2, 20.1±0.2, 21.8±0.2, 22.6±0.2, 24.0±0.2, 25.1±0.2, and 27.5±0.2.

### Claim 62 (depends on 9)

The compound of claim 9, wherein the pharmaceutically acceptable salt is meglumine salt.

### Claim 63 (depends on 62)

The compound of claim 62, wherein Compound A meglumine salt is a solid form and has an X-ray diffraction pattern with at least three characteristic peaks expressed in values of degrees 2θ selected from those at 3.4±0.2, 5.6±0.2, 8.8±0.2, 11.3±0.2, 14.0±0.2, 17.1±0.2, 20.5±0.2, 22.0±0.2, 24.0±0.2, 26.5±0.2, and 28.8±0.2.

### Claim at position 45

64-65. (canceled)

### Claim 66 (depends on 9)

A method of antagonizing cyclic GMP-AMP synthase (cGAS) in a patient in need thereof, comprising administering an effective amount of a compound of claim 9.

### Claim 67 (depends on 9)

A method of treating an inflammatory, allergic, autoimmune, or neurodegenerative disease in a patient in need thereof, comprising administering an effective amount of a compound of claim 9.

### Claim at position 48

68-70. (canceled)
